Vanguard Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
Other funds holding FDMT
Vanguard Capital Management's FDMT Position: Q3 2026 in Review
Vanguard Capital Management increased its 4D Molecular Therapeutics (FDMT) stake by 2% in Q3 2026, buying an estimated $543K and bringing the position to 2,140,758 shares worth $30.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2167.
Vanguard Capital Management first reported a position in FDMT in Q1 2026 and has held it in 3 quarters since. 167 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.
- Vanguard Capital Management held 2,140,758 shares of 4D Molecular Therapeutics worth $30.6M as of Q3 2026.
- Vanguard Capital Management bought 41,703 4D Molecular Therapeutics shares in Q3 2026, an estimated $543K.
- 4D Molecular Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2167 holding.
- Vanguard Capital Management first reported a position in 4D Molecular Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 167 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.